Skip to content
2000
Volume 15, Issue 6
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Despite being long lived, anthracyclines remain the “evergreen” drugs in clinical practice of oncology, showing a potent effect in inhibiting cell growth in many types of tumors, including brain neoplasms. Unfortunately, they suffer from a poor penetration into the brain when intravenously administered due to multidrug resistance mechanism, which hampers their delivery across the blood brain barrier. In this paper, we summarize the current literature on the role of anthracyclines in cancer therapy and highlight recent efforts on 1) development of tumor cell resistance to anthracyclines and 2) the new approaches to brain drug delivery across the blood brain barrier.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520615666150407155319
2015-07-01
2025-05-06
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520615666150407155319
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test